Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.87
BDX's Cash to Debt is ranked higher than
67% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. BDX: 0.87 )
BDX' s 10-Year Cash to Debt Range
Min: 0.04   Max: 1.03
Current: 0.87

0.04
1.03
Equity to Asset 0.27
BDX's Equity to Asset is ranked higher than
51% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. BDX: 0.27 )
BDX' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.63
Current: 0.27

0.27
0.63
Interest Coverage 11.90
BDX's Interest Coverage is ranked higher than
62% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.78 vs. BDX: 11.90 )
BDX' s 10-Year Interest Coverage Range
Min: 7.22   Max: 42.29
Current: 11.9

7.22
42.29
F-Score: 7
Z-Score: 3.59
M-Score: -2.90
WACC vs ROIC
9.28%
19.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.59
BDX's Operating margin (%) is ranked higher than
89% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.34 vs. BDX: 18.59 )
BDX' s 10-Year Operating margin (%) Range
Min: 14.62   Max: 22.75
Current: 18.59

14.62
22.75
Net-margin (%) 13.56
BDX's Net-margin (%) is ranked higher than
89% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. BDX: 13.56 )
BDX' s 10-Year Net-margin (%) Range
Min: 7.59   Max: 18.49
Current: 13.56

7.59
18.49
ROE (%) 22.21
BDX's ROE (%) is ranked higher than
94% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. BDX: 22.21 )
BDX' s 10-Year ROE (%) Range
Min: 15.67   Max: 28.17
Current: 22.21

15.67
28.17
ROA (%) 8.50
BDX's ROA (%) is ranked higher than
86% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.71 vs. BDX: 8.50 )
BDX' s 10-Year ROA (%) Range
Min: 6.66   Max: 14.79
Current: 8.5

6.66
14.79
ROC (Joel Greenblatt) (%) 31.55
BDX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.05 vs. BDX: 31.55 )
BDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 23.63   Max: 46.7
Current: 31.55

23.63
46.7
Revenue Growth (3Y)(%) 8.40
BDX's Revenue Growth (3Y)(%) is ranked higher than
83% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BDX: 8.40 )
BDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.4   Max: 11.9
Current: 8.4

4.4
11.9
EBITDA Growth (3Y)(%) 5.00
BDX's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 223 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. BDX: 5.00 )
BDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 1.9   Max: 15.7
Current: 5

1.9
15.7
EPS Growth (3Y)(%) 4.10
BDX's EPS Growth (3Y)(%) is ranked higher than
73% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. BDX: 4.10 )
BDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -0.6   Max: 21.9
Current: 4.1

-0.6
21.9
» BDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BDX Guru Trades in Q1 2014

Steven Cohen 61,535 sh (+2293.43%)
Paul Tudor Jones 6,600 sh (+46.86%)
Jim Simons 1,342,000 sh (+19.92%)
Pioneer Investments 1,010,161 sh (+2.49%)
Chris Davis 3,635 sh (unchged)
Ruane Cunniff 2,272 sh (unchged)
Bill Frels 5,188 sh (unchged)
Vanguard Health Care Fund 2,571,700 sh (unchged)
Arnold Van Den Berg Sold Out
Jeff Auxier 43,450 sh (-1.47%)
Dodge & Cox 16,880 sh (-2.88%)
Richard Pzena 2,537,209 sh (-3.7%)
Manning & Napier Advisors, Inc 2,399,462 sh (-5.2%)
Jeremy Grantham 1,621,998 sh (-6.36%)
Mario Gabelli 550,705 sh (-7.86%)
Robert Olstein 57,000 sh (-12.31%)
Michael Price 175,000 sh (-12.5%)
Yacktman Fund 660,000 sh (-15.38%)
John Hussman 100,000 sh (-20%)
Donald Yacktman 1,300,476 sh (-25.8%)
Ray Dalio 2,995 sh (-30.27%)
Yacktman Focused Fund 450,000 sh (-32.84%)
» More
Q2 2014

BDX Guru Trades in Q2 2014

Joel Greenblatt 80,303 sh (New)
Jean-Marie Eveillard 582,656 sh (New)
John Hussman 175,000 sh (+75%)
Jim Simons 1,550,700 sh (+15.55%)
Paul Tudor Jones 6,842 sh (+3.67%)
Richard Pzena 2,600,468 sh (+2.49%)
Pioneer Investments 1,018,372 sh (+0.81%)
Donald Yacktman 1,304,228 sh (+0.29%)
Manning & Napier Advisors, Inc 2,400,462 sh (+0.04%)
Yacktman Fund 660,000 sh (unchged)
Michael Price 135,000 sh (unchged)
Yacktman Focused Fund 450,000 sh (unchged)
Ruane Cunniff 2,272 sh (unchged)
Chris Davis Sold Out
Ray Dalio Sold Out
Dodge & Cox 16,780 sh (-0.59%)
Mario Gabelli 544,832 sh (-1.07%)
Bill Frels 5,088 sh (-1.93%)
Robert Olstein 54,000 sh (-5.26%)
Vanguard Health Care Fund 2,393,100 sh (-6.94%)
Jeff Auxier 39,950 sh (-8.06%)
Jeremy Grantham 1,431,598 sh (-11.74%)
Michael Price 135,000 sh (-22.86%)
» More
Q3 2014

BDX Guru Trades in Q3 2014

Ray Dalio 25,358 sh (New)
Paul Tudor Jones 13,358 sh (+95.24%)
Jean-Marie Eveillard 829,770 sh (+42.41%)
Jim Simons 2,198,100 sh (+41.75%)
Joel Greenblatt 101,597 sh (+26.52%)
Richard Pzena 2,731,408 sh (+5.04%)
Robert Olstein 54,000 sh (unchged)
Pioneer Investments 1,007,206 sh (unchged)
Yacktman Focused Fund 450,000 sh (unchged)
Vanguard Health Care Fund 2,393,100 sh (unchged)
Michael Price 135,000 sh (unchged)
Yacktman Fund 660,000 sh (unchged)
Ruane Cunniff Sold Out
Donald Yacktman 1,303,596 sh (-0.05%)
Jeff Auxier 39,900 sh (-0.13%)
Bill Frels 5,053 sh (-0.69%)
Dodge & Cox 16,510 sh (-1.61%)
Jeremy Grantham 1,363,503 sh (-4.76%)
Mario Gabelli 501,272 sh (-8%)
Manning & Napier Advisors, Inc 1,771,592 sh (-26.2%)
John Hussman 50,000 sh (-71.43%)
» More
Q4 2014

BDX Guru Trades in Q4 2014

Steven Cohen 528,800 sh (New)
Jim Simons 2,648,700 sh (+20.5%)
Vanguard Health Care Fund 2,635,600 sh (+10.13%)
John Hussman 50,000 sh (unchged)
Bill Frels 5,053 sh (unchged)
Yacktman Focused Fund Sold Out
Donald Yacktman Sold Out
Yacktman Fund Sold Out
Joel Greenblatt Sold Out
Manning & Napier Advisors, Inc Sold Out
Dodge & Cox 15,730 sh (-4.72%)
Pioneer Investments 956,515 sh (-5.03%)
Jeff Auxier 37,875 sh (-5.08%)
Jeremy Grantham 1,280,701 sh (-6.07%)
Robert Olstein 48,000 sh (-11.11%)
Mario Gabelli 423,359 sh (-15.54%)
Jean-Marie Eveillard 668,683 sh (-19.41%)
Paul Tudor Jones 6,919 sh (-48.2%)
Ray Dalio 9,758 sh (-61.52%)
Michael Price 40,000 sh (-70.37%)
Richard Pzena 402,735 sh (-85.26%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Pzena 2014-12-31 Reduce -85.26%1.45%$114.12 - $141.26 $ 146.7212%402735
Michael Price 2014-12-31 Reduce -70.37%1.34%$114.12 - $141.26 $ 146.7212%40000
Yacktman Fund 2014-12-31 Sold Out 0.65%$114.12 - $141.26 $ 146.7212%0
Donald Yacktman 2014-12-31 Sold Out 0.62%$114.12 - $141.26 $ 146.7212%0
Yacktman Focused Fund 2014-12-31 Sold Out 0.55%$114.12 - $141.26 $ 146.7212%0
Joel Greenblatt 2014-12-31 Sold Out 0.12%$114.12 - $141.26 $ 146.7212%0
Ray Dalio 2014-12-31 Reduce -61.52%0.01%$114.12 - $141.26 $ 146.7212%9758
John Hussman 2014-09-30 Reduce -71.43%1.14%$112.63 - $120.21 $ 146.7226%50000
Jean-Marie Eveillard 2014-09-30 Add 42.41%0.07%$112.63 - $120.21 $ 146.7226%829770
Joel Greenblatt 2014-09-30 Add 26.52%0.03%$112.63 - $120.21 $ 146.7226%101597
Ray Dalio 2014-09-30 New Buy0.02%$112.63 - $120.21 $ 146.7226%25358
Ruane Cunniff 2014-09-30 Sold Out $112.63 - $120.21 $ 146.7226%0
John Hussman 2014-06-30 Add 75%0.69%$111.18 - $120.33 $ 146.7226%175000
Jean-Marie Eveillard 2014-06-30 New Buy0.17%$111.18 - $120.33 $ 146.7226%582656
Joel Greenblatt 2014-06-30 New Buy0.12%$111.18 - $120.33 $ 146.7226%80303
Ray Dalio 2014-06-30 Sold Out $111.18 - $120.33 $ 146.7226%0
Chris Davis 2014-06-30 Sold Out $111.18 - $120.33 $ 146.7226%0
Michael Price 2014-03-31 Reduce -12.5%0.36%$105.4 - $116.81 $ 146.7230%175000
Yacktman Focused Fund 2014-03-31 Reduce -32.84%0.26%$105.4 - $116.81 $ 146.7230%450000
Donald Yacktman 2014-03-31 Reduce -25.8%0.2%$105.4 - $116.81 $ 146.7230%1300476
John Hussman 2014-03-31 Reduce -20%0.2%$105.4 - $116.81 $ 146.7230%100000
Robert Olstein 2014-03-31 Reduce -12.31%0.12%$105.4 - $116.81 $ 146.7230%57000
Yacktman Fund 2014-03-31 Reduce -15.38%0.12%$105.4 - $116.81 $ 146.7230%660000
Arnold Van Den Berg 2014-03-31 Sold Out 0.02%$105.4 - $116.81 $ 146.7230%0
Ray Dalio 2014-03-31 Reduce -30.27%$105.4 - $116.81 $ 146.7230%2995
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.50
BDX's P/E(ttm) is ranked higher than
87% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.60 vs. BDX: 24.50 )
BDX' s 10-Year P/E(ttm) Range
Min: 10.23   Max: 30.81
Current: 24.5

10.23
30.81
Forward P/E 18.83
BDX's Forward P/E is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.95 vs. BDX: 18.83 )
N/A
PE(NRI) 24.50
BDX's PE(NRI) is ranked higher than
87% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.30 vs. BDX: 24.50 )
BDX' s 10-Year PE(NRI) Range
Min: 13.02   Max: 27.63
Current: 24.5

13.02
27.63
P/B 5.57
BDX's P/B is ranked higher than
61% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.67 vs. BDX: 5.57 )
BDX' s 10-Year P/B Range
Min: 2.96   Max: 5.64
Current: 5.57

2.96
5.64
P/S 3.43
BDX's P/S is ranked higher than
69% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. BDX: 3.43 )
BDX' s 10-Year P/S Range
Min: 1.99   Max: 3.54
Current: 3.43

1.99
3.54
PFCF 26.48
BDX's PFCF is ranked higher than
86% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.01 vs. BDX: 26.48 )
BDX' s 10-Year PFCF Range
Min: 13.37   Max: 32.56
Current: 26.48

13.37
32.56
POCF 16.60
BDX's POCF is ranked higher than
83% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. BDX: 16.60 )
BDX' s 10-Year POCF Range
Min: 8.76   Max: 17.48
Current: 16.6

8.76
17.48
EV-to-EBIT 18.47
BDX's EV-to-EBIT is ranked higher than
86% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.45 vs. BDX: 18.47 )
BDX' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 19.8
Current: 18.47

9.8
19.8
PEG 5.10
BDX's PEG is ranked higher than
87% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. BDX: 5.10 )
BDX' s 10-Year PEG Range
Min: 0.92   Max: 7.5
Current: 5.1

0.92
7.5
Shiller P/E 24.31
BDX's Shiller P/E is ranked higher than
92% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 155.01 vs. BDX: 24.31 )
BDX' s 10-Year Shiller P/E Range
Min: 13.79   Max: 33.31
Current: 24.31

13.79
33.31
Current Ratio 2.74
BDX's Current Ratio is ranked higher than
91% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. BDX: 2.74 )
BDX' s 10-Year Current Ratio Range
Min: 1.23   Max: 2.76
Current: 2.74

1.23
2.76
Quick Ratio 2.07
BDX's Quick Ratio is ranked higher than
92% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. BDX: 2.07 )
BDX' s 10-Year Quick Ratio Range
Min: 0.73   Max: 2.1
Current: 2.07

0.73
2.1
Days Inventory 130.84
BDX's Days Inventory is ranked higher than
70% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 129.97 vs. BDX: 130.84 )
BDX' s 10-Year Days Inventory Range
Min: 103.84   Max: 154.55
Current: 130.84

103.84
154.55
Days Sales Outstanding 51.30
BDX's Days Sales Outstanding is ranked higher than
91% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.21 vs. BDX: 51.30 )
BDX' s 10-Year Days Sales Outstanding Range
Min: 51.3   Max: 86.75
Current: 51.3

51.3
86.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.52
BDX's Dividend Yield is ranked higher than
57% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.36 vs. BDX: 1.52 )
BDX' s 10-Year Dividend Yield Range
Min: 0.95   Max: 2.44
Current: 1.52

0.95
2.44
Dividend Payout 0.38
BDX's Dividend Payout is ranked higher than
98% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. BDX: 0.38 )
BDX' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.36
Current: 0.38

0.19
0.36
Dividend growth (3y) 10.00
BDX's Dividend growth (3y) is ranked higher than
77% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.50 vs. BDX: 10.00 )
BDX' s 10-Year Dividend growth (3y) Range
Min: 2.6   Max: 29.1
Current: 10

2.6
29.1
Yield on cost (5-Year) 2.43
BDX's Yield on cost (5-Year) is ranked higher than
64% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. BDX: 2.43 )
BDX' s 10-Year Yield on cost (5-Year) Range
Min: 1.54   Max: 3.95
Current: 2.43

1.54
3.95
Share Buyback Rate 4.40
BDX's Share Buyback Rate is ranked higher than
97% of the 233 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.60 vs. BDX: 4.40 )
BDX' s 10-Year Share Buyback Rate Range
Min: 6   Max: -1.1
Current: 4.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.92
BDX's Price/Tangible Book is ranked higher than
64% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. BDX: 9.92 )
BDX' s 10-Year Price/Tangible Book Range
Min: 3.36   Max: 14.99
Current: 9.92

3.36
14.99
Price/DCF (Projected) 1.71
BDX's Price/DCF (Projected) is ranked higher than
85% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.95 vs. BDX: 1.71 )
BDX' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 3.32
Current: 1.71

1
3.32
Price/Median PS Value 1.28
BDX's Price/Median PS Value is ranked higher than
70% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. BDX: 1.28 )
BDX' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.29
Current: 1.28

0.6
1.29
Price/Graham Number 3.24
BDX's Price/Graham Number is ranked higher than
81% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.66 vs. BDX: 3.24 )
BDX' s 10-Year Price/Graham Number Range
Min: 1.63   Max: 4.96
Current: 3.24

1.63
4.96
Earnings Yield (Greenblatt) 5.40
BDX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. BDX: 5.40 )
BDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5   Max: 10.2
Current: 5.4

5
10.2
Forward Rate of Return (Yacktman) 7.07
BDX's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.36 vs. BDX: 7.07 )
BDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7   Max: 19.7
Current: 7.07

7
19.7

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 9,313 10,426 13,883
EPS($) 6.59 7.71 9.98
EPS without NRI($) 6.59 7.71 9.98

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BOX.Germany, BDX.Switzerland,
Becton Dickinson & Co was incorporated under the laws of the State of New Jersey in November 1906. The Company is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Its operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces an array of medical devices that are used in a range of healthcare settings. They include many safety-engineered injection, infusion and surgery products. BD Medical's product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefill able drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; and sharps disposal containers. BD Diagnostics provide products for the safe collection and transport of diagnostic specimens, as well as instrument systems and reagents to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. BD Diagnostics' products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. BD Biosciences' product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The customers served by BD Biosciences are research and clinical laboratories; academic and government institutions; pharmaceutical and biotechnology companies; hospitals; and blood banks. The products sold by BD outside the United States are needles and syringes; insulin syringes and pen needles; diagnostic systems; BD VacutainerTM brand blood collection products; BD HypakTM brand prefillable syringe systems; infusion therapy products; flow cytometry instruments and reagents; and disposable laboratory products. It has manufacturing operations outside the United States, Brazil, Canada, China, Fr
» More Articles for BDX

Headlines

Articles On GuruFocus.com
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
Becton and Dickinson´s Expansion into Emerging Markets Feb 10 2015 
ok Jan 31 2015 
The World’s Top 10 Financial Bloggers Jan 12 2015 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Dividend Aristocrats in Focus Part 18 of 54: Becton, Dickinson & Company Oct 14 2014 
Weekly 52-Week Highs Highlight: BDX, DUK, CFN, INFY Oct 12 2014 
Becton and Dickinson Provides Shareholders with Solid Returns Oct 03 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Critical Investor John Hussman's Top Five Q2 Holdings Aug 01 2014 

More From Other Websites
BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing Feb 26 2015
Diamonds of the Polish Infrastructure for Budimex Feb 25 2015
Polish Hercules 2014 for Budimex and President Blocher Feb 25 2015
Budimex to build hospital in Zabki near Warsaw Feb 24 2015
Relational reduces position in Hologic Feb 19 2015
Current report no 7 / 2015 Feb 19 2015
Current report no 6 / 2015 Feb 19 2015
Current report no 8 / 2015 Feb 19 2015
Commentary on selected financial data for 2014 Feb 18 2015
Cramer's hottest stocks on the market right now Feb 17 2015
'Mad Money' Lightning Round: Buy, Buy, Buy Popeyes Louisiana Kitchen Feb 14 2015
BECTON DICKINSON & CO Financials Feb 13 2015
Current report no 5 / 2015 Feb 13 2015
This Low-Volatility ETF Deserves Your Attention Feb 13 2015
Current report no 3 / 2015 Feb 12 2015
Current report no 4 / 2015 Feb 12 2015
CareFusion to Distribute Breas Medical's Vivo Ventilators in US - Analyst Blog Feb 10 2015
Moody's: Large healthcare acquirers will show different rates of deleveraging in 2015 Feb 10 2015
EU mergers and takeovers (Feb 9) Feb 09 2015
EU mergers and takeovers (Feb 9) Feb 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK